Roles of Community Pharmacists in Screening and Disseminating of Information about Non-Steroidal Anti-Inflammatory Drugs Risks: Implications for Drug Safety Assessment
Background: The increasing use of non-steroidal anti-inflammatory drugs (NSAIDs) both on prescription and over the counter raises a major global health concern because of the risks associated with their use if no proper guidance is given by the health care provider. This study assessed the roles of community pharmacists in screening and disseminating information about the risks associated with NSAID use in Zambia. Methodology: This was a national cross-sectional study in which a structured self-administered questionnaire was administered to 245 registered community pharmacists in Zambia. Stata/BE, version 15.1 (Stata Corporation, College Station, Texas, USA) and multivariate logistic regression model was used to determine factors associated with information dissemination about ADRs of NS-NSAIDs. Results: 231 of the 245 distributed questionnaires were returned giving a response rate of 94.3%. All (100%) participating community pharmacists claimed to have practiced dispensing NSAIDs. However, only 26 (11.0%) and 71 (30.8%) regularly screened for risk factor of selective COX-2 NSAIDS (SC2-NSAIDS) and non-selective NSAIDS (NS-NSAIDs) respectively. Information dissemination on adverse drug reactions (ADRs) of SC2-NSAIDS was regularly provided by only 22 (9.5%) of pharmacists while that of NS-NSAIDs was regularly provided by 49 (21.2%). In the multivariate logistic regression model, being the owner of a pharmacy (AOR: 5.4, CI: 1.84 - 16.4) was significantly associated with information dissemination about ADRs of NS-NSAIDs while an hour increase in the working hours per day (AOR: 0.9, CI: 0.64 - 0.95) was associated with less likelihood of information dissemination. Conclusion: Pharmacists working in community pharmacies in Zambia did not regularly screen and disseminate information about the risks associated with NSAID use. Therefore, pharmacists should be able to screen and monitor patients at risk and be aware of the majority of risk factors while dispensing NSAIDs to minimize the associated complications.
References
[1]
Gorczyca, P., Manniello, M., Pisano, M. and Avena-Woods, C. (2016) NSAIDs: Balancing the Risks and Benefits. U.S. Pharmacist, 41, 24-26.
[2]
Fokunang, C., Fokunang, E., Frederick, K., Ngameni, B. and Ngadjui, B. (2018) Overview of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in Resource Limited Countries. MOJ Toxicology, 4, 5-13. https://doi.org/10.15406/mojt.2018.03.00081
[3]
Balamurugan, J. and Lakshmanan, M. (2021) Non-Steroidal Anti-Inflammatory Medicines. In: Paul, A., Anandabaskar, N., Mathaiyan, J. and Raj, G.M., Eds., Introduction to Basics of Pharmacology and Toxicology, Springer, Singapore, 335-352. https://doi.org/10.1007/978-981-33-6009-9_19
[4]
Phueanpinit, P., Pongwecharak, J., Krska, J. and Jarernsiripornkul, N. (2018) Evaluation of Community Pharmacists’ Roles in Screening and Communication of Risks about Non-Steroidal Anti-Inflammatory Drugs in Thailand. Primary Health Care Research & Development, 19, 598-604. https://doi.org/10.1017/S1463423618000142
[5]
Wehling, M. (2014) Non-Steroidal Anti-Inflammatory Drug Use in Chronic Pain Conditions with Special Emphasis on the Elderly and Patients with Relevant Comorbidities: Management and Mitigation of Risks and Adverse Effects. European Journal of Clinical Pharmacology, 70, 1159-1172. https://doi.org/10.1007/s00228-014-1734-6
[6]
Lim, C.C., Ang, A.T.W., Kadir, H.B.A., Lee, P.H., Goh, B.Q., Harikrishnan, S., Kwek, J.L., Gan, S.S., Choo, J.C.J. and Tan, N.C. (2021) Short-Course Systemic and Topical Non-Steroidal Anti-Inflammatory Drugs: Impact on Adverse Renal Events in Older Adults with Co-Morbid Disease. Drugs & Aging, 38, 147-156. https://doi.org/10.1007/s40266-020-00824-4
[7]
Gokul, A.J., Chandur, V.K. and Shabaraya, A.R. (2023) Non Selective Cox Inhibitor NSAIDs Induced Nephropathy a Systematic Review. International Journal of Pharmaceutical Sciences, 1, 433-440.
[8]
Ingrasciotta, Y., Sultana, J., Giorgianni, F., Caputi, A.P., Arcoraci, V., Tari, D.U., Linguiti, C., Perrotta, M., Nucita, A. and Pellegrini, F. (2014) The Burden of Nephrotoxic Drug Prescriptions in Patients with Chronic Kidney Disease: A Retrospective Population-Based Study in Southern Italy. PLOS ONE, 9, e89072. https://doi.org/10.1371/journal.pone.0089072
[9]
Rothenberg, R.J. and Holcomb, J.P. (2000) Guidelines for Monitoring of NSAIDs Who Listened? JCR: Journal of Clinical Rheumatology, 6, 258-265. https://doi.org/10.1097/00124743-200010000-00005
[10]
Meuwesen, W.P., Du Plessis, J.M., Burger, J.R., Lubbe, M.S. and Cockeran, M. (2016) Prescribing Patterns of Non-Steroidal Anti-Inflammatory Drugs in Chronic Kidney Disease Patients in the South African Private Sector. International Journal of Clinical Pharmacy, 38, 863-869. https://doi.org/10.1007/s11096-016-0298-1
[11]
Al-Shidhani, A., Al-Rawahi, N. and Al-Rawahi, A. (2015) Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Use in Primary Health Care Centers in A’Seeb, Muscat: A Clinical Audit. Oman Medical Journal, 30, 366-371. https://doi.org/10.5001/omj.2015.73
[12]
Barakat, H.E., Aziz, C.N. and Abougalambou, S.S.I. (2023) Evaluation of the Knowledge, Practices, and Attitudes of Community Pharmacists towards Adverse Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs): A Cross-Sectional Study. Journal of Pharmaceutical Policy and Practice, 16, Article 132. https://doi.org/10.1186/s40545-023-00641-1
[13]
Antman, E.M., Bennett, J.S., Daugherty, A., Furberg, C., Roberts, H. and Taubert, K.A. (2007) Use of Nonsteroidal Antiinflammatory Drugs: An Update for Clinicians: A Scientific Statement from the American Heart Association. Circulation, 115, 1634-1642. https://doi.org/10.1161/CIRCULATIONAHA.106.181424
[14]
Schmitt, M.R., Miller, M.J., Harrison, D.L., Farmer, K.C., Allison, J.J., Cobaugh, D.J. and Saag, K.G. (2011) Communicating Non-Steroidal Anti-Inflammatory Drug Risks: Verbal Counseling, Written Medicine Information, and Patients’ Risk Awareness. Patient Education and Counseling, 83, 391-397. https://doi.org/10.1016/j.pec.2010.10.032
[15]
Mangum, S.A., Kraenow, K.R. and Narducci, W.A. (2003) Identifying At-Risk Patients through Community Pharmacy-Based Hypertension and Stroke Prevention Screening Projects. Journal of the American Pharmaceutical Association (1996), 43, 50-55. https://doi.org/10.1331/10865800360467042
[16]
Bond, C. and Hannaford, P. (2003) Issues Related to Monitoring the Safety of Over-the-Counter (OTC) Medicines. Drug Safety, 26, 1065-1074. https://doi.org/10.2165/00002018-200326150-00001
[17]
Mosler, C. (2014) Cardiovascular Risk Associated with NSAIDs and COX-2 Inhibitors. U.S. Pharmacist, 39, 35-38.
[18]
Alchin, J., Dhar, A., Siddiqui, K. and Christo, P.J. (2022) Why Paracetamol (Acetaminophen) Is a Suitable First Choice for Treating Mild to Moderate Acute Pain in Adults with Liver, Kidney or Cardiovascular Disease, Gastrointestinal Disorders, Asthma, or Who Are Older. Current Medical Research and Opinion, 38, 811-825. https://doi.org/10.1080/03007995.2022.2049551
[19]
Jang, S.M., Cerulli, J., Grabe, D.W., Fox, C., Vassalotti, J.A., Prokopienko, A.J. and Pai, A.B. (2014) Peer Reviewed: NSAID-Avoidance Education in Community Pharmacies for Patients at High Risk for Acute Kidney Injury, Upstate New York, 2011. Preventing Chronic Disease, 11, E220.
[20]
Jarernsiripornkul, N., Phueanpinit, P., Pongwecharak, J. and Krska, J. (2019) Development and Evaluation of User-Tested Thai Patient Information Leaflets for Non-Steroidal Anti-Inflammatory Drugs: Effect on Patients’ Knowledge. PLOS ONE, 14, e0210395. https://doi.org/10.1371/journal.pone.0210395
[21]
Smith, K., Durant, K.M. and Zimmerman, C. (2022) Impact of an Electronic Health Record Alert on Inappropriate Prescribing of High-Risk Medications to Patients with Concurrent “Do Not Give” Orders. American Journal of Health-System Pharmacy, 79, 1198-1204. https://doi.org/10.1093/ajhp/zxac092
[22]
Dawson, K.G., Mok, V., Wong, J.G. and Bhalla, A. (2023) Deprescribing Initiative of NSAIDs (DIN): Pharmacist-Led Interventions for Pain Management in a Federal Correctional Setting. Canadian Pharmacists Journal/Revue des Pharmaciens du Canada, 156, 85-93. https://doi.org/10.1177/17151635221149712
[23]
Davies, M.J., Collings, M., Fletcher, W. and Mujtaba, H. (2014) Pharmacy Apps: A New Frontier on the Digital Landscape? Pharmacy Practice, 12, Article 453. https://doi.org/10.4321/S1886-36552014000300009
[24]
Crilly, P., Hassanali, W., Khanna, G., Matharu, K., Patel, D., Patel, D., Rahman, F. and Kayyali, R. (2019) Community Pharmacist Perceptions of Their Role and the Use of Social Media and Mobile Health Applications as Tools in Public Health. Research in Social and Administrative Pharmacy, 15, 23-30. https://doi.org/10.1016/j.sapharm.2018.02.005
[25]
Osterhaus, J.T., Dedhiya, S.D., Ernst, M.E., Osterhaus, M., Mehta, S.S. and Townsend, R.J. (2002) Health Outcomes Assessment in Community Pharmacy Practices: A Feasibility Project. Arthritis Care & Research: Official Journal of the American College of Rheumatology, 47,124-131. https://doi.org/10.1002/art.10291
[26]
Teichert, M., Griens, F., Buijs, E., Wensing, M. and De Smet, P.A. (2014) Effectiveness of Interventions by Community Pharmacists to Reduce Risk of Gastrointestinal Side Effects in Nonselective Nonsteroidal Anti-Inflammatory Drug Users. Pharmacoepidemiology and Drug Safety, 23, 382-389. https://doi.org/10.1002/pds.3587
[27]
Owusu, Y.B., Elkhalifa, W.H., Awaisu, A. and Kheir, N. (2022) Assessment of Qatar Community Pharmacists’ Competence and Practices Related to Renal and Gastrointestinal Adverse Effects of Nonprescription NSAIDs. Saudi Pharmaceutical Journal, 30, 1396-1404. https://doi.org/10.1016/j.jsps.2022.06.011
[28]
Alomar, M. (2014) Community Pharmacy Prescription Screening in the UAE. Pharmacology & Pharmacy, 5, 83-91. https://doi.org/10.4236/pp.2014.51013
[29]
Malebari, A.M., Khayyat, A.N., Mahdali, R.A., Alamoudi, J.S., Alsayed, B.Y. and Alrasheed, S.A. (2020) Evaluation of the Community Pharmacists’ Performance in the Screening of Non-Steroidal Anti-Inflammatory Drugs Risks in Saudi Arabia. Saudi Medical Journal, 41, 849-857. https://doi.org/10.15537/smj.2020.8.25221
[30]
Ilardo, M.L. and Speciale, A. (2020) The Community Pharmacist: Perceived Barriers and Patient-Centered Care Communication. International Journal of Environmental Research and Public Health, 17, Article 536. https://doi.org/10.3390/ijerph17020536
[31]
Qudah, B., Thakur, T. and Chewning, B. (2021) Factors Influencing Patient Participation in Medication Counseling at the Community Pharmacy: A Systematic Review. Research in Social and Administrative Pharmacy, 17, 1863-1876. https://doi.org/10.1016/j.sapharm.2021.03.005
[32]
Jick, H. (1994) Risk of Upper Gastrointestinal Bleeding and Perforation Associated with Individual Non-Steroidal Anti-Inflammatory Drugs. The Lancet, 343, 769-772. https://doi.org/10.1016/S0140-6736(94)91843-0
[33]
Baker, M. and Perazella, M.A. (2020) NSAIDs in CKD: Are They Safe? American Journal of Kidney Diseases, 76, 546-557. https://doi.org/10.1053/j.ajkd.2020.03.023
[34]
Rafaniello, C., Ferrajolo, C., Sullo, M.G., Sessa, M., Sportiello, L., Balzano, A., Manguso, F., Aiezza, M.L., Rossi, F. and Scarpignato, C. (2016) Risk of Gastrointestinal Complications Associated to NSAIDs, Low-Dose Aspirin and Their Combinations: Results of a Pharmacovigilance Reporting System. Pharmacological Research, 104, 108-114. https://doi.org/10.1016/j.phrs.2015.12.026
[35]
Luanghirun, P., Tanaboriboon, P., Mahissarakul, P., Tongruang, C., Chaichirawiwat, C., Piyaraj, P., Narindrarangkura, P. and Lertvivatpong, N. (2017) Prevalence and Associated Factors of Regular Nonsteroidal Anti-Inflammatory Drugs Used in a Rural Community, Thailand. Global Journal of Health Science, 9, 58-67. https://doi.org/10.5539/gjhs.v9n9p58
[36]
Pai, A.B. (2015) Keeping Kidneys Safe: The Pharmacist’s Role in NSAID Avoidance in High-Risk Patients. Journal of the American Pharmacists Association, 55, E15-E25. https://doi.org/10.1331/JAPhA.2015.15506
[37]
Brennan, R., Wazaify, M., Shawabkeh, H., Boardley, I., McVeigh, J. and Van Hout, M.C. (2021) A Scoping Review of Non-Medical and Extra-Medical Use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). Drug Safety, 44, 917-928. https://doi.org/10.1007/s40264-021-01085-9
[38]
Abougalambou, S.S., Abdoun, S.A. and SayerAlharbi, N. (2019) Awareness of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Use Among Population in Saudi Arabia. Open Journal of Pharmaceutical Science and Research, 1, 40-52. https://doi.org/10.36811/ojpsr.2019.110003
[39]
Jarernsiripornkul, N., Phueanpinit, P., Pongwecharak, J. and Krska, J. (2019) Practices of Healthcare Professionals in Communicating with Nonsteroidal Anti-Inflammatory Drug Users in Thailand: A Qualitative Study. International Journal of Pharmacy Practice, 27, 362-369. https://doi.org/10.1111/ijpp.12538
[40]
Koffeman, A.R., Valkhoff, V.E., Çelik, S., W’T Jong, G., Sturkenboom, M.C.J.M., Bindels, P.J.E., Van Der Lei, J., Luijsterburg, P.A.J. and Bierma-Zeinstra, S.M.A. (2014) High-Risk Use of over-the-Counter Non-Steroidal Anti-Inflammatory Drugs: A Population-Based Cross-Sectional Study. British Journal of General Practice, 64, e191-e198. https://doi.org/10.3399/bjgp14X677815
